Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Interview · December 01, 2019

Circulating Myeloid-Derived Suppressor Cells as a Predictor for Patients Treated With Nivolumab and Bevacizumab for Recurrent GBM

Farzanna Haffizulla MD, FACP, FAMWA
Manmeet Ahluwalia MD, FACP, MBA

 

 Save  Recommend
 Share

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Watched This Week

Related Videos